Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). FDA accepted NDA for lorundrostat to treat adult hypertension (in combination with other antihypertensive drugs): key regulatory milestone toward commercialization.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA accepted NDA for lorundrostat to treat adult hypertension (in combination with other antihypertensive drugs): key regulatory milestone toward commercialization
- NDA acceptance triggers PDUFA date assignment, moving lorundrostat closer to potential approval and market launch
- Company simultaneously released topline Phase 2 Explore-OSA trial results, expanding lorundrostat's potential indication pipeline beyond hypertension
Item 8.01 · Other Events
- FDA accepted NDA for lorundrostat (hypertension combination therapy); PDUFA action date set for December 22, 2026: key regulatory catalyst
- Phase 2 Explore-OSA trial missed primary endpoint: lorundrostat 50mg failed to show clinically meaningful AHI reduction vs. placebo in obstructive sleep apnea
- Strong BP signal in OSA trial: lorundrostat reduced systolic BP by 11.1 mmHg (p<0.0001) vs. 1.0 mmHg placebo; 6.2 mmHg placebo-adjusted reduction in crossover analysis
- Clean safety profile in OSA trial: no potassium excursions above 5.5 mmol/L; supports tolerability narrative for core hypertension NDA
- Near-term focus shifts entirely to December 2026 FDA decision; OSA miss removes a potential label expansion opportunity but doesn't derail primary indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.